Elypta wins Nordic Life Science Award 2019

At the annual Nordic Life Science Days, Elypta was announced the winner of the Nordic Life Science Award as well as the Delegates’ Choice Award, the latter voted for by the delegates at the conference. Elypta was awarded for their achievement in combining distinguished science and technology to create a disruptive platform for the early detection of cancer.


Karl Bergman
Elypta announces initiation of the pivotal AURORAX-087A study

Elypta has initiated preparations for the AURORAX-087 study to generate evidence to support regulatory approval for the first application, monitoring of recurrence in renal cell carcinoma patients. The study is the largest so far centered around kidney cancer diagnostics. Factory-CRO, a CRO specialised in clinical trial management in medtech and IVD was recently selected for the managment of the study.

First Word Medtech covered the announcement here:


Karl Bergman
Elypta nominated for Best Technological Innovation in Diagnostics by Medtech Insight

Elypta is a finalist in this year’s Medtech Insight Awards, an award that celebrates and recognizes excellence among the companies, teams, and individuals driving positive change across the global medtech industry.

Elypta is nominated for Best Technological Innovation: Diagnostics.

“We are delighted with this nomination,” says Karl Bergman, CEO of Elypta. “Accurate, rapid and cost-effective diagnostics are essential to fulfill the promise of precision medicine and we believe we need to find markers also in metabolism to achieve this. We are already gaining a great deal of interest in the US for our approach and this nomination will help raise our profile further.”


Karl Bergman
Elypta named Nordic start-up of the year in the Serendipity Challenge

Elypta participated in the Serendipity Challenge finals at Techarenan in Almedalen, Visby - a focal point for Swedish industry and policymakers at an annual gathering in July every year. Elypta was one of 50 selected start-ups among over 400 applicants.

Following initial pitches to a jury of investors and subsequent presentations by the top 7 companies to the audience at Techarenan, Elypta was awarded Nordic Start-up of the year for its rapid progress towards introducing novel biomarkers for early detection of cancer. The competition is in its 5th year and attracts start-ups from across sectors, focusing on Tech.

The award is a great recognition for the efforts of the team over the last year.

Karl Bergman
Elypta visited by Dr Robert Langer

Elypta had the great pleasure to host Dr. Robert Langer, Institute Professor at MIT and long time advisor for our company, and his son Sam. We are grateful also for the US Embassy’s assistance in accomodating the visit.

Karl Bergman
In-depth article on Elypta in 360Dx

The Horizon 2020 award announcement has led to increased interest in Elypta’s activities. 360Dx interviewed Karl Bergman (CEO) and Saeed Dabestani, Urologic surgeoun at Skåne University Hospital, senior associate at the European Association of Urology, Guidelines panel for RCC and medical advisor to Elypta on the application of the technology in RCC. Full article here.

Karl Bergman
Elypta awarded €2.35 million from Horizon 2020 SME instrument

Elypta today announced it is one of the winners in the European Union’s Horizon 2020 Research and Innovation Programme SME instrument phase 2 and has been awarded Euros 2.35 m. The grant will fund the first ever multicenter trial for diagnoses of renal cell carcinoma (RCC), aimed at validating the company's innovative metabolism-based liquid biopsy platform for early detection of recurrent RCC and thus enabling the test to be launched in Europe and the US.

Swedish press release

Select press coverage:

Nordic Life Science

Life Science Sweden



Karl Bergman